Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that it exceeded its revenue target for the financial year 2005 of "up to 5%" growth over 2004 (2004: EUR 72.7 million). Based on preliminary 2005 revenues, following a strong Q4 business, full year growth will be 9%. Higher growth resulted from a stronger than planned sales performance in the Company's Services Division and the achievement of the first milestone in the Alzheimer's disease collaboration with Takeda.
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Evotec AG, Schnackenburgallee 114, 22525 Hamburg, Germany, Phone: +49.(0)40.560 81-286, firstname.lastname@example.org